I tried to organize the "characteristics" behind how to prescribe a diabetes drug and reduce HbA1c on one page. Please have a look.

The number of patients with HbA1c of 6.3% or less has continued since 2008.

Furthermore, since the launch of SGLT2 inhibitors, HbA1c has dropped by 0.4% to that level, and more and more patients have HbA1c of around 6%.

In the case of diabetes, fundus hemorrhage is extremely unlikely to occur unless HbA1c exceeds 6.5%.

Therefore, it is extremely rare for outpatients at our hospital to get worse even if they have fundus hemorrhage.

In addition, the combined use of DPP4 inhibitors and SGLT2 inhibitors has recently led to a large number of patients experiencing improvement in diabetic nephropathy. There are an increasing number of cases in which even patients who have been suffering from diabetic nephropathy have noticeably improved GFR by receiving treatment at our hospital. The number of patients whose urinary protein is improved to +-or negative by our treatment, even if it is 4+ at the first visit, is increasing.

If you are worried that HbA1c will not be reduced by the current treatment and you may be on dialysis in the future, and you have to do something about it now, please come to our hospital. Please give me.

In modern times, it is possible to sufficiently prevent diabetic nephropathy by using various prescription drugs within the insurance medical treatment frame.